Navigation Links
For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
Date:5/18/2009

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the treatment of rheumatoid arthritis, the market share for TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of the increasing use of alternative agents to treat the disease. In 2008, TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira accounted for 80 percent of rheumatoid arthritis drug sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative biologics such as Roche/Chugai's Actemra/RoActemra will take market share away from the TNF-alpha inhibitors as interviewed rheumatologists indicate they switch to one of these agents for patients who respond inadequately to two TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred agent for TNF-refractory patients and is forecasted to achieve sales of nearly $2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and is expected to take significant market share away from Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the indication following its recent approval for rheumatoid arthritis by the Food and Drug Administration. Additionally, an emerging agent from Pfizer is expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal patient share from the
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes
2. Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
3. Sodium channel blocker shows promise as a potential treatment for cystic fibrosis
4. The future of personalized cancer treatment: An entirely new direction for RNAi delivery
5. An Aid to Tailoring Prostate Cancer Treatment
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
8. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
9. Can New Surgery Revolutionize Diabetes Treatment?
10. Chicago-area Infertility Specialist Richard Sherbahn, MD, Reports a Woman's Body Mass Index Affects Her Success in Infertility Treatment
11. New Cancer Treatment Achieves First Mesothelioma Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Top medical tourism firm, VisitandCare.com ... the Dominican Republic to benefit from the experience of ... the medical tourism industry upside-down and becoming a choice ... services becoming the central influence. , “Trust is ... are not only attracted to low-cost surgical enhancement, but ...
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 DrugDev announced ... (Liss) Easy was named to the 2015 Philadelphia Business ... 40 list spotlights 40 dynamic, up-and-coming leaders less than ... community involvement. Winners are honored at an awards program ... the Philadelphia Business Journal. , Lyn Kremer, Publisher of ...
(Date:3/27/2015)... According to Health Day , ... Neonatal Abstinence Syndrome (NAS) are causing alarm for Florida ... withdrawal process for a month of their lives- and ... and vomiting. The condition is precipitated by drug use ... treatment (and employing medically assisted drug treatment) will also ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 California’s ongoing ... blizzards in Boston and the United States Northeast, are ... Earth warming global atmosphere is creating changes in the ... historical climatologist and former NASA researcher, speaking on the ... result is not only a warmer and dryer global ...
Breaking Medicine News(10 mins):Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3
... Denise Mann HealthDay Reporter , MONDAY, July ... juice or capsules for the treatment and prevention of ... antibiotics may be more effective even if they contribute ... are less effective in the prevention, but do not ...
... 26, 2011] Antibiotic overuse and resistance have emerged as ... outbreak of Clostridium difficile infections, which often result from ... physicians and pharmacists with an education campaign that reduced ... Clinical Infectious Diseases and now available ...
... 2011Better data are needed to evaluate access to care ... as older African Americans, and to assess the benefits ... health information technology and access to multilevel diabetes education ... Management , a peer-reviewed journal published by Mary Ann ...
... July 25 (HealthDay News) -- Hospitalized patients who are able ... satisfied with their care, but one-fifth are not given the ... The authors of the new study compiled information on the ... three-year period, and had the patients rate their sense of ...
... MONDAY, July 25 (HealthDay News) -- The varicella vaccine has nearly ... study shows. The vaccine, introduced in a one-dose form ... all age groups and by 97 percent in young people 20 ... Immunization and Respiratory Diseases. "This is one of our ...
... Southwestern Medical Center researchers have narrowed the potential drug ... tumors are driven by a different hormonal pathway than ... known to stimulate the growth of the disease, advanced ... actually is driven by a pathway that circumvents the ...
Cached Medicine News:Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 2Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 3Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:New data-based strategies and treatment models can improve diabetes care for older African-Americans 2Health News:Spiritual Talks May Boost Patients' View of Hospital Care 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 3Health News:UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer 2
(Date:3/27/2015)... As of February, InControl Medical, LLC ... women. "Shipping thousands of our devices ... the hundreds of letters, emails and phone calls ... positively impacted by our technology," said Herschel ... recently released Apex, an over-the-counter solution for female ...
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
...   Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), ... president and chief executive officer of Pacira Pharmaceuticals, is scheduled ... Tuesday, September 20, 2011, at 11 a.m. EDT to be ... Center in New York City. Mr. Stack is expected to ...
... 2011 VIVUS, Inc. (NASDAQ: VVUS ) ... study in diabetics.  In the REVIVE-Diabetes study (TA-302), male ...  Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado ... study during the poster session at the 47th European ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference 2Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 2Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 3Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: